翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 天安卓健有限公司 呈交日期： 2025年4月30日 FF305 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | | 00383 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股 ...

MEDICARE （於百慕達註冊成立之有限公司） (Incorporated in Bermuda with limited liability) (Stock Code: 383) （股份代號：383） NOTIFICATION LETTER 通知信函 11 April 2025 Dear Non-registered Shareholder(s) (Note), Tian An Medicare Limited (the "Company") — Notice of Publication of 2024 Annual Report, Circular together with Notice of Annual General Meeting and Proxy Form (the "Current Corporate Communications") The English and Chinese versions of the Current Corporate Communication are available on the Company's websites at www.tiananme ...

MEDICARE （於百慕達註冊成立之有限公司） (Incorporated in Bermuda with limited liability) (Stock Code: 383) （股份代號：383） NOTIFICATION LETTER 通知信函 11 April 2025 Dear Registered Shareholder(s), Tian An Medicare Limited (the "Company") — Notice of Publication of 2024 Annual Report, Circular together with Notice of Annual General Meeting and Proxy Form (the "Current Corporate Communications") The English and Chinese versions of the Current Corporate Communication are available on the Company's websites at www.tiananmedicare.com. ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 MEDICARE （於百慕達註冊成立之有限公司） （股份代號：383） 股東週年大會通告 茲通告 天 安 卓 健 有 限 公 司（「本 公 司」）謹 訂 於 二 零 二 五 年 五 月 十 九 日（星 期 一）上 午 十一時正假座香港灣仔謝斐道238號香港諾富特世紀酒店B3層1–2號宴會廳召開 股 東 週 年 大 會（「股 東 週 年 大 會」），以 便 討 論 下 列 決 議 案： – 1 – 1. 省覽及採納截至二零二四年十二月三十一日止年度之經審核財務報表與董 事會報告及核數師報告。 2. 宣布派發截至二零二四年十二月三十一日止年度每股2港仙之末期股息。 3. (A) (a) 重選江木賢先生為董事。 (b) 重選高兆元先生為董事。 (c) 重選夏曉寧博士為董事。 (d) 重選王永權博士為董事。 (e) 重選張園園女士為董事。 (f) 重選曹丹先生為董事。 (B) 授 權 董 事 會（「董 事 會」 ...

此乃要件 請即處理 閣下如已售出或轉讓 所 有 名 下 之 天 安 卓 健 有 限 公 司（「本 公 司」）股 份，應 立 即 將 本 通 函、隨 附 之代表委任表格及二零二四年年報送交買方或承讓人，或經手出售或轉讓之銀行、股票經紀 或其他代理人，以便轉交買方或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本通函全部或任何部份內容而產生或 因倚賴該等內容而引致之任何損失承擔任何責任。 MEDICARE （於百慕達註冊成立之有限公司） （股份代號：383） 重選董事、 發行證券及購回股份之 一般授權之建議 及 本 公 司 謹 定 於 二 零 二 五 年 五 月 十 九 日（星 期 一）上 午 十 一 時 正 假 座 香 港 灣 仔 謝 斐 道238號香港 諾富特世紀酒店B3層1-2號 宴 會 廳 舉 行 股 東 週 年 大 會（「股 東 週 年 大 會」），股 東 週 年 大 會 通 告 載於本通函第16至19頁。無論 閣下能否出席股東週年大會，務請儘快將隨附之代表委任表 格按照其上印列之指示填妥，並儘早交回本公司於香 ...

（股份代號：383） （於百慕達註冊成立之有限公司） 2024 環境、社會及 管治報告 環境、社會及管治報告 | 目錄 | | --- | | 董事會致辭 | 2 | | --- | --- | | 報告界限 | 3 | | 報告準則 | 3 | | 報告原則 | 3 | | 可持續發展管治 | 4 | | 持份者參與 | 4 | | 重要性評估 | 5 | | 環境議題 | 6 | | • 排放物 （層面A1 ） | 6 | | ） • 資源使用 （層面A2 | 9 | | • 環境及天然資源 （層面A3 ） | 11 | | • 氣候變化 （層面A4 ） | 11 | | 社會議題 | 12 | | • 僱傭 （層面B1 ） | 12 | | • 健康與安全 （層面B2 ） | 14 | | • 發展及培訓 （層面B3 ） | 16 | | • 勞工標準 （層面B4 ） | 17 | | • 供應鏈管理 （層面B5 ） | 18 | | • 產品責任 （層面B6 ） | 21 | | • 反貪污 （層面B7 ） | 24 | | • 社區投資 （層面B8 ） | 25 | 1 二零二四環境、社會及管治報告 ...

Financial Performance - The group recorded total revenue of HKD 1,627,199,000 for the year ended December 31, 2024, representing an increase of approximately 3.49% compared to HKD 1,572,305,000 for the previous year[6]. - Profit attributable to shareholders increased to HKD 28,773,000, a significant rise of approximately 96.03% from HKD 14,678,000 in the previous year[6]. - The basic earnings per share for the year ended December 31, 2024, was HKD 0.0265, compared to HKD 0.0159 for the previous year[7]. - The board proposed a final dividend of HKD 0.02 per share, up from HKD 0.01 per share in the previous year[8]. - The gross profit for 2024 is HKD 336,220,000, compared to HKD 290,334,000 in 2023, indicating an increase of about 15.8%[190]. - Operating profit for 2024 is HKD 86,118,000, slightly down from HKD 88,612,000 in 2023, reflecting a decrease of approximately 1.7%[190]. - The profit before tax for 2024 is HKD 57,004,000, up from HKD 40,805,000 in 2023, marking an increase of about 39.7%[190]. - The annual profit for 2024 is HKD 41,976,000, compared to HKD 25,893,000 in 2023, which is an increase of approximately 62.2%[190]. - The company incurred financing costs of HKD 29,114,000 in 2024, a significant decrease from HKD 47,807,000 in 2023, indicating a reduction of approximately 39.2%[190]. Medical Segment Performance - The medical segment generated revenue of HKD 1,581,036,000, an increase from HKD 1,521,859,000 in the previous year, with a profit of HKD 119,991,000 compared to HKD 87,023,000 previously[12]. - EBITDA for the medical segment reached HKD 222,479,000, up from HKD 202,095,000 in the previous year[12]. - Nanjing Hospital recorded a total of 1,040,998 outpatient visits, 38,144 inpatient admissions, and 51,716 health check-ups in the review year, compared to 1,084,533 outpatient visits, 34,730 inpatient admissions, and 61,377 health check-ups in the previous year[19]. - Kunming Hospital achieved 476,111 outpatient visits, 21,628 inpatient admissions, and 58,111 health check-ups, an increase from 449,657 outpatient visits, 21,543 inpatient admissions, and 68,146 health check-ups in the previous year[19]. - The medical division plans to enhance service quality and patient experience through streamlined processes and innovative care models[48]. Challenges and Market Conditions - The group faced challenges in the second quarter of 2024 due to a decline in macroeconomic conditions and weakened consumer demand[12]. - The group is focused on expanding its medical services and enhancing operational efficiency amid changing market conditions[11]. - The elderly care division is implementing a new property management business to enhance revenue amid increased competition and member attrition[21]. - The company will adopt a prudent approach in response to ongoing global trade tensions, geopolitical conflicts, and economic weakness, adjusting its business and investment strategies accordingly[50]. Investment and Property Management - The group's rental income from investment properties in Hong Kong and China for the year ended December 31, 2024, was HKD 4,336,000, down from HKD 5,124,000 in 2023, resulting in a loss of HKD 8,363,000 compared to a profit of HKD 5,289,000 in 2023[26]. - The fair value loss on investment properties was HKD 10,680,000 for the year ended December 31, 2024, compared to a gain of HKD 1,009,000 in 2023[26]. - The total value of the group's investment properties decreased to HKD 197,240,000 as of December 31, 2024, from HKD 207,920,000 in 2023[26]. - The company has engaged independent valuation experts to assess the appropriateness of valuation methods and key assumptions used in the fair value measurement of investment properties[180]. - Investment properties account for approximately 15% of total assets, highlighting their significance in the consolidated financial statements[179]. Shareholder and Governance Matters - The company has established a governance framework with six committees to assist in fulfilling its responsibilities[140]. - The board consists of 11 members, including 3 executive directors, 4 non-executive directors, and 4 independent non-executive directors[122]. - The company has adopted a compensation policy for employees based on merits, qualifications, and performance, with the compensation committee making recommendations for directors' remuneration[110]. - The company has complied with the corporate governance code as per the Hong Kong Stock Exchange[119]. - The company holds annual and special general meetings to facilitate communication between shareholders and the Board, with a 100% attendance rate from directors at the last annual meeting[164]. Risk Management and Compliance - The company has established a risk management framework consisting of the Board of Directors, the Audit Committee, and a dedicated Risk Management Task Force to oversee business operation risks[155]. - The internal audit function assists the Board and Audit Committee in continuously monitoring the effectiveness of the risk management and internal control systems[156]. - The company is committed to ensuring compliance with legal and regulatory requirements through regular reviews and monitoring[142]. - The company has implemented a whistleblower policy to allow employees and stakeholders to report concerns anonymously regarding any improper matters[157]. Future Outlook and Strategic Plans - The company plans to continue its strategy of investment and management in healthcare and hospital operations, as well as property investment and development[11]. - The elderly care division will focus on creating smart elderly care communities by enhancing member services and optimizing elder programs by 2025[49]. - The company aims to enhance overall operational efficiency and attract more residents through optimized admission policies[49].

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 00383 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年4月7日 | | 1 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 天安卓健有限公司 呈交日期： 2025年4月7日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | | 00383 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | | ...

Core Insights - The article discusses the significant progress made in Guangdong's electricity market reform over the past decade, highlighting its transformation into a model for other regions in China [1][4]. Group 1: Market Transformation - Guangdong's electricity market has evolved from "price difference transmission" to "price linkage" and from "only decreasing prices" to "both increasing and decreasing prices" [1]. - The market has transitioned from intermittent to continuous operation, with Guangdong being the first province to implement long-term centralized trading and pilot spot market settlements [1][4]. Group 2: Market Participation - The number of registered market participants in Guangdong has surged from 0.07 million in 2016 to 79,000 by March 2025, marking an increase of nearly 112 times [3]. - The installed capacity of market participants has reached 164 million kilowatts, accounting for 73.5% of the province's total installed capacity [2]. Group 3: Cost Reduction and Efficiency - The electricity market in Guangdong has reduced costs for industrial and commercial users by approximately 35.5 billion yuan, driven by a combination of factors including falling coal prices and increased market competition [4]. - The average price for medium to long-term trading has decreased from 0.449 yuan per kilowatt-hour in 2024 to 0.392 yuan per kilowatt-hour in 2025 [4]. Group 4: Supply and Consumption - Since the continuous operation of the spot market began in November 2021, Guangdong has maintained a low non-scheduled power generation capacity reduction rate of 1.5%, the lowest in the country [5]. - The province has achieved a 99.7% consumption rate for renewable energy, with green electricity trading volumes increasing by 83% year-on-year in 2024 [5]. Group 5: Future Directions - Guangdong aims to establish a comprehensive market trading mechanism that includes distributed photovoltaics, virtual power plants, and charging stations, addressing challenges for mass purchasing users [6].